FOR IMMEDIATE RELEASE
Middleton, WI, November 15, 2004 – Bone Care International, Inc. (Nasdaq: BCII) announced today that the Company will be added to the NASDAQ Biotechnology IndexÒ effective as of Monday, November 22, 2004.
“Bone Care International is honored to be included in the NASDAQ Biotechnology Index,” said Paul L. Berns, President and Chief Executive Officer. “The outstanding performance of our organization and our increased visibility in the investment community have enabled the Company to meet the requirements for this prominent Index. This is an important accomplishment for Bone Care as we strive to expand our business and organization to better serve patients and healthcare professionals and build future value for our shareholders.”
Launched in 1993, the NASDAQ Biotech Index includes companies classified according to the FTSE ™ Global Classification System as either biotechnology or pharmaceutical. The index is ranked on a semi-annual basis in May and November. All securities in the Index are listed on the NASDAQ National Market and must meet minimum requirements, including market value, average daily share volume and seasoning as a public company among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit www.nasdaq.com.
About Bone Care International
Bone Care International (www.bonecare.com) is a specialty pharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our current commercial and therapeutic focus is in nephrology, utilizing Hectorol®, a novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the Company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasis.
Contacts
Bone Care International, Inc.
Brian J. Hayden
Chief Financial Officer
(608) 662-7800
Rx Communications Group, LLC
Melody A. Carey (Investors)
(917) 322-2571
Tony Loke (Media)
(917) 322-2164
This press release contains forward-looking statements. Statements relating to future sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, the ability of the Company and each of its suppliers of doxercalciferol, Hectorol® Injection and Hectorol® Capsules to meet the Company’s anticipated production schedules, technical risks associated with the development of new products, regulatory policies in the United States and other countries, risks associated with our ability to avoid or minimize delays in/or interruption of the manufacture and supply of our products, including the approvals of regulatory authorities in connection therewith, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company’s operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.
